Rhythm Pharmaceuticals
RYTM
89 hedge funds and large institutions have $973M invested in Rhythm Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 43 increasing their positions, 16 reducing their positions, and 14 closing their positions.
169% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 16
36% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 14
31% more capital invested
Capital invested by funds: $741M → $973M (+$232M)
6% more funds holding
Funds holding: 84 → 89 (+5)
2.91% less ownership
Funds ownership: 99.38% → 96.47% (-2.9%)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$49M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$44.4M |
| 3 |
Primecap Management
Pasadena,
California
|
+$41M |
| 4 |
DM
Deerfield Management
New York
|
+$37.8M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$20M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TG
TRV GP
Boston,
Massachusetts
|
-$38.5M |
| 2 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
-$15.1M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$11.7M |
| 4 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$5.06M |
| 5 |
Millennium Management
New York
|
-$4.85M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
101
Tower Research Capital (TRC)
New York
| – | -$13K | -603 | Closed |
|
102
Twin Tree Management
Dallas,
Texas
| – | -$6K | -284 | Closed |
|
103
Fifth Third Bancorp
Cincinnati,
Ohio
| – | -$3K | -137 | Closed |
|
RYTM Hedge Fund Activity: Q4 2019 in Review
89 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q4 2019, worth a combined $973M — up 31% from $741M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new RYTM positions and 14 closed out — a net gain of 5 holders — while 43 added to existing stakes and 16 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $49M. The largest seller was TRV GP, exiting entirely with an estimated $38.5M sold.
- 89 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q4 2019, up from 84 in Q3 2019.
- Funds reported $973M of Rhythm Pharmaceuticals stock for Q4 2019, up 31% quarter-over-quarter.
- 19 funds opened new Rhythm Pharmaceuticals positions in Q4 2019 and 14 closed out, a net change of +5 holders.
- The largest Rhythm Pharmaceuticals buyer in Q4 2019 was Wellington Management Group, an estimated $49M added.
- The largest Rhythm Pharmaceuticals seller in Q4 2019 was TRV GP, an estimated $38.5M sold.
Based on aggregated 13F filings for Q4 2019.